<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296777</url>
  </required_header>
  <id_info>
    <org_study_id>#4781</org_study_id>
    <nct_id>NCT00296777</nct_id>
  </id_info>
  <brief_title>Treatment of Depression Following Multiple Brain Tests</brief_title>
  <official_title>Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to correlate brain testing with treatment outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 medication-free Depressed Patients will receive a battery of neuropsychologic tests,
      standard dichotic listening tests, EEG, ERP and an f-MRI while performing a neuropsychologic
      test, the Simon. Once testing is completed, patients will be treated in an open treatment
      trial of SSRI. Non-responders will then receive Bupropion followed by Tricyclic
      Antidepressant if still depressed. While our main purpose is to correlate imaging testing
      with other measures of brain functioning, we also intend to see whether f-MRI findings
      demonstrate specific brain areas which differ between responders and non-responders. At the
      end of SSRI treatment, patients will have a second f-MRI scan to investigate any changes
      treatment and/or response may have caused.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale (HAM-D)</measure>
    <time_frame>7 mos.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI)</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inventory of Depressive Symptoms (IDS)</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Handedness Inventory</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chapman Pleasure Scale</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spielberger State/Trait Anxiety Inventory</measure>
    <time_frame>7 mos.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Major Depression</condition>
  <condition>Dysthymia</condition>
  <arm_group>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>8 weeks: up to 40 mg/day</description>
    <arm_group_label>escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.</description>
    <arm_group_label>bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>8 weeks: up to 300mg/day
*if patient does not have contraindication.</description>
    <arm_group_label>imipramine</arm_group_label>
    <other_name>Tofranil, Pressamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV Major Depression or Dysthymia

          -  Age 18-65

          -  Physically healthy

          -  Normal hearing

          -  Drug-free (two weeks for most antidepressants, four weeks for Fluoxetine)

        Exclusion Criteria:

          -  Hearing deficit in one or both ears

          -  Body metal (e.g., wire stitches, screws in bones, stainless steel hips)

          -  History of Psychosis or Epilepsy

          -  Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)

          -  Unstable medical problem

          -  Insufficient English for neuropsychological and dichotic testing

          -  Bipolar I

          -  Need for wash-out from effective treatment in order to participate

          -  Pregnant

          -  High suicide risk

          -  Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan W. Stewart, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute - Columbia University Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Evaluation Service - New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depression-nyc.org</url>
    <description>Depression Evaluation Service - official website</description>
  </link>
  <link>
    <url>http://www.nyspi.org</url>
    <description>New York State Psychiatric Institute - official website</description>
  </link>
  <reference>
    <citation>Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006 Jan;163(1):73-8.</citation>
    <PMID>16390892</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, Voglmaier MM, Harrison WM, McGrath P, Tricamo E, Quitkin FM. Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology. 1990 Feb;3(1):1-10.</citation>
    <PMID>2306330</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Otto MW, McGrath PJ, Stewart JW, Fava M, Rosenbaum JF, Quitkin FM. Dichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic response. Neuropsychopharmacology. 1996 Aug;15(2):171-9.</citation>
    <PMID>8840353</PMID>
  </reference>
  <reference>
    <citation>Stewart JW, Quitkin FM, McGrath PJ, Bruder GE. Do tricyclic responders have different brain laterality? J Abnorm Psychol. 1999 Nov;108(4):707-10.</citation>
    <PMID>10609436</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001 Mar 1;49(5):416-25.</citation>
    <PMID>11274653</PMID>
  </reference>
  <reference>
    <citation>Bruder GE, Stewart JW, McGrath PJ, Deliyannides D, Quitkin FM. Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men. Neuropsychopharmacology. 2004 Sep;29(9):1752-61.</citation>
    <PMID>15238992</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Dysthymia</keyword>
  <keyword>f-MRI</keyword>
  <keyword>Escitalopram</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Neuropsychologic test</keyword>
  <keyword>Dichotic listening</keyword>
  <keyword>EEG</keyword>
  <keyword>ERP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Imipramine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

